Efficient and comprehensive sports drug testing necessitates frequent updating and proactive, preventive anti-doping research and the early implementation of new, emerging drugs into routine doping controls is an essential aspect. Several new drugs and drug candidates with potential for abuse, including so-called Rycals (ryanodine receptor calstabin complex stabilizers, for example, S-107), hypoxia-inducible factor (HIF) stabilizers and peroxisome-proliferator-activated receptor (PPAR) δ agonists (for example, GW1516), were studied using different mass spectrometry- and ion mobility-based approaches and their gas-phase dissociation behaviors were elucidated. The detailed knowledge of fragmentation routes allows a more rapid identification of metabolites and structurally related, presumably “tailor-made”, analogs potentially designed for doping purposes. The utility of product ion characterization is demonstrated, in particular, with GW1516, for which oxidation products were readily identified in urine samples by means of diagnostic fragment ions, as measured using high-resolution/high-accuracy mass spectrometry and higher energy collision-induced dissociation (HCD).
BellingerA.M.MongilloM.MarksA.R., “Stressed out: The skeletal muscle ryanodine receptor as a target of stress”, J. Clin. Invest.118, 445 (2008). doi: 10.1172/JCI34006
2.
BellingerA.M.ReikenS.DuraM.MurphyP.W.DengS.X.LandryD.W.NiemanD.LehnartS.E.SamaruM.LaCampagneA.MarksA.R., “Remodeling of ryanodine receptor complex causes “leaky” channels: A molecular mechanism for decreased exercise capacity”, Proc. Natl. Acad. Sci. USA.105, 2198 (2008). doi: 10.1073/pnas.0711074105
OchiR.GupteS.A., “Ryanodine receptor: A novel therapeutic target in heart disease”, Recent Patents Cardiovasc. Drug Discov.2, 110 (2007).
5.
WehrensX.H.LehnartS.E.MarksA.R., “Ryanodine receptor-targeted anti-arrhythmic therapy”, Ann. NY Acad. Sci.1047, 366 (2005). doi: 10.1196/annals.1341.032
6.
WehrensX.H.LehnartS.E.ReikenS.van der NagelR.MoralesR.SunJ.ChengZ.DengS.X.de WindtL.J.LandryD.W.MarksA.R., “Enhancing calstabin binding to ryanodine receptors improves cardiac and skeletal muscle function in heart failure”, Proc. Natl. Acad. Sci. USA102, 9607 (2005). doi: 10.1073/pnas.0500353102
7.
WehrensX.H.LehnartS.E.ReikenS.R.DengS.X.VestJ.A.CervantesD.CoromilasJ.LandryD.W.MarksA.R., “Protection from cardiac arrhythmia through ryanodine receptor-stabilizing protein calstabin2”, Science304, 292 (2004). doi: 10.1126/science.1094301
8.
BruickR., “Oxygen sensing in the hypoxic response pathway: Regulation of the hypoxia-inducible transcription factor”, Genes Dev.17, 2614 (2003). doi: 10.1101/gad.1145503
9.
HäggM.WennströmS., “Activation of hypoxia-induced transcription in normoxia”, Exp. Cell Res.306, 180 (2005). doi: 10.1016/j.yexcr.2005.01.017
10.
HuangL.E.BunnH.F., “Hypoxia-inducible factor and its biomedical relevance”, J. Biol. Chem.278, 19575 (2003). doi: 10.1074/jbc.R200030200
11.
RapisardaA.UranchimegB.ScudieroD.SelbyM.SausvilleE.ShoemakerR.MelilloG., “Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway”, Cancer Res.62, 4316 (2002).
12.
RatcliffeP., “From erythropoietin to oxygen: Hypoxia-inducible factor hydroxylases and the hypoxia signal pathway”, Blood. Purif.20, 445 (2002). doi: 10.1159/000065201
13.
LuquetS.Lopez-SorianoJ.HolstD.GaudelC.Jehl-PietriC.FredenrichA.GrimaldiP.A., “Roles of peroxisome proliferator-activated receptor delta (PPARdelta) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome”, Biochimie86, 833 (2004). doi: 10.1016/j.bio-chi.2004.09.024
14.
TanakaT.YamamotoJ.IwasakiS.AsabaH.HamuraH.IkedaY.WatanabeM.MagooriK.IokaR.X.TachibanaK.WatanabeY.UchiyamaY.SumiK.IguchiH.ItoS.DoiT.HamakuboT.NaitoM.AuwerxJ.YanagisawaM.KodamaT.SakaiJ., “Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome”, Proc. Natl. Acad. Sci. USA100, 15924 (2003). doi: 10.1073/pnas.0306981100
ThevisM.ThomasA.KohlerM.BeuckS.SchänzerW., “Emerging drugs: Mechanism of action, mass spectrometry and doping control analysis”, J. Mass Spectrom.44, 442 (2009). doi: 10.1002/jms.1584
18.
ThevisM.BeuckS.ThomasA.FußhöllerG.SchlörerN.SchäferM.SchänzerW., “Electron ionization mass spectrometry of the ryanodine-based Ca2+-channel stabilizer S-107 and its implementation into routine doping control”, Rapid Commun. Mass Spectrom.23, 2363 (2009). doi: 10.1002/rcm.4161
19.
ThevisM.BeuckS.ThomasA.KohlerM.SchlörerN.VajialaI.SchänzerW., “Screening for the calstabin–ryanodine–receptor complex stabilizers JTV-519 and S-107 in doping control analysis”, Drug Test. Analysis1, 32 (2009). doi: 10.1002/dta.13
20.
ThevisM.KohlerM.SchlörerN.SchänzerW., “Gas phase reaction of substituted isoquinolines to carboxylic acids in ion trap and triple quadrupole mass spectrometers after electrospray ionization and collision-induced dissociation”, J. Am. Soc. Mass Spectrom.19, 151 (2008). doi: 10.1016/j.jasms.2007.11.003
21.
ThevisM.BeuckS.ThomasA.KortnerB.KohlerM.RodchenkovG.SchänzerW., “Doping control analysis of emerging drugs in human plasma—identification of GW501516, S-107, JTV-519 and S-40503”, Rapid Commun. Mass Spectrom.23, 1139 (2009). doi: 10.1002/rcm.3987
22.
ThevisM.GeyerH.MareckU.SchänzerW., “Screening for unknown synthetic steroids in human urine by liquid chromatography-tandem mass spectrometry”, J. Mass Spectrom.40, 955 (2005). doi: 10.1002/jms.873
LideD.R. (Ed), Handbook of Chemistry and Physics, CRC Press, CRC Press, Boca Raton, Florida, USA (2008).
26.
WysockiV.H.TsaprailisG.SmithL.L.BreciL.A., “Mobile and localized protons: A framework for understanding peptide dissociation”, J. Mass Spectrom.35, 1399 (2000). doi: 10.1002/1096-9888(200012)35:12<1399::AID-JMS86>3.0.CO;2-R
27.
SafranM.KaelinW.G.Jr, “HIF hydroxylation and the mammalian oxygen-sensing pathway”, J. Clin. Invest.111, 779 (2003).
WangQ.GouG.GuenzlerV.NeffT.KlausS.TurtleE.MolineauxC.YeowellD.LinA., “Stimulation of erythropoiesis and treatment of anemia in rodents by oral administration of FG-2216, a novel HIF-prolyl hydroxylase inhibitor”, J. Am. Soc. Nephrol.15, 773A (2004).
32.
HsiehM.M.LindeN.S.WynterA.MetzgerM.WongC.LangsetmoI.LinA.SmithR.RodgersG.P.DonahueR.E.KlausS.J.TisdaleJ.F., “HIF prolyl hydroxy lase inhibition results in endogenous erythropoietin induction, erythrocytosis and modest fetal hemoglobin expression in rhesus macaques”, Blood110, 2140 (2007). doi: 10.1182/blood-2007-02-073254
33.
Fibrogen (2005) inEuropean Patent Office, European Patent Office, Germany.
KrämerD.K.Al-KhaliliL.GuigasB.LengY.Garcia-RovesP.M.KrookA., “Role of AMP kinase and PPARdelta in the regulation of lipid and glucose metabolism in human skeletal muscle”, J. Biol. Chem.282, 19313 (2007). doi: 10.1074/jbc.M702329200
36.
BrunmairB.StaniekK.DorigJ.SzocsZ.StadlbauerK.MarianV.GrasF.AnderwaldC.NohlH.WaldhauslW.FurnsinnC., “Activation of PPAR-delta in isolated rat skeletal muscle switches fuel preference from glucose to fatty acids”, Diabetologia49, 2713 (2006). doi: 10.1007/s00125-006-0357-6
37.
NarkarV.A.DownesM.YuR.T.EmblerE.WangY.X.BanayoE.MihaylovaM.M.NelsonM.C.ZouY.JuguilonH.KangH.ShawR.J.EvansR.M., “AMPK and PPARdelta agonists are exercise mimetics”, Cell134, 405 (2008). doi: 10.1016/j.cell.2008.06.051
38.
WangY.X.ZhangC.L.YuR.T.ChoH.K.NelsonM.C.Bayuga-OcampoC.R.HamJ.KangH.EvansR.M., “Regulation of muscle fiber type and running endurance by PPARdelta”, PLoS Biol.2, e294 (2004). doi: 10.1371/journal.pbio.0020294
